A “hard stop” requiring providers to think critically about C difficile testing in the presence of laxative use or absence of documented diarrhea strengthened CDI testing stewardship.
All articles by Brandon May
Fixed dose delafloxacin IV/oral monotherapy was comparable to vancomycin/aztreonam in patients with ABSSSI and gram-positive pathogens.
Traditional risk factors may incur a higher risk for CVD in HIV-positive premenopausal women than HIV infection itself.
Incidence of adverse events with delafloxacin (Baxdela™, Melinta Therapeutics) was comparable to the combination regimen of vancomycin plus aztreonam across 2 phase 3 registrational ABSSSI studies.